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ackground & Aims: Screening guidelines for
olorectal cancer include colonoscopy starting at
ge 50 years based on the prevalence of adenomas
nd the incidence of colon cancer at that age. How-
ver, only one prior study has investigated the prev-
lence of colorectal neoplasia with colonoscopic
creening in asymptomatic average-risk individuals
ges 40–49 years in the United States. Methods: We
nalyzed the results of screening colonoscopies of-
ered to patients of a health care provider that
ffers screening services as part of an employer-
rovided wellness program. The primary end
oints were prevalence of adenomas and cancers
or those aged 40–49 years vs those 50–59 years.
esults: We analyzed 553 screening colonoscopies
or patients ages 40–49 years and 352 screening
olonoscopies for patients ages 50–59 years. In the
0–49 years age group, 79 patients (14%) had 1 or
ore adenomas, of which 11 (2% of screened) had an
dvanced neoplasm (>1 cm). In the 50–59 years age
roup, 56 patients (16%) had 1 or more adenomas de-
ected. Of those patients, 13 (3.7% of screened) had an
dvanced neoplasm, and 1 patient (0.3%) had an adeno-
arcinoma detected. Conclusions: We found on
olonoscopic screening that the prevalence of total
denomas was similar in individuals ages 40–49 and
n those 50–59 years, although the prevalence of ad-
anced neoplasia in the 50–59 years age group may be
igher than that in the 40–49 years age group.
olonoscopy is an effective and widely endorsed mo-
dality for screening for colorectal cancer. In recent
ears, colonoscopy was the primary driving force for the
verall increase in colorectal cancer screening.1 There is
ompelling evidence that screening colonoscopy with re-
oval of detected polyps leads to a substantial reductionn the incidence of colorectal cancer, with its efficacy
ivaling or superior to annual fecal occult blood test-
ng, flexible sigmoidoscopy, and double contrast bar-
um enema.2–4
Guidelines from multiple professional societies recom-
end screening colonoscopy beginning at age 50 years
or average-risk individuals.5–7 This age cutoff is based
argely on the fact that the incidence of colorectal cancer
egins to rise in the sixth decade of life.8 However, given
he long lead time associated with the adenoma to car-
inoma progression, the increased number of colorectal
ancers diagnosed in this age group may reflect the end
esult of adenomas present in individuals in their forties.
ence, these cancers may be prevented by colonoscopy
ith polypectomy of premalignant lesions in the preced-
ng decade. Despite this theoretic argument for screening
ndividuals in their forties, only one prior study has
nvestigated the prevalence of colorectal neoplasia with
olonoscopic screening in asymptomatic average-risk in-
ividuals aged 40–49 years in the United States.9 In this
tudy, we investigated the prevalence of colorectal neo-
lasia, including potentially premalignant adenomas, in
symptomatic individuals at average risk aged 40–49
ears undergoing colonoscopic screening and compared
t with findings in individuals aged 50–59 years.
Materials and Methods
Executive Health Exams International, Inc. (EHE)
s a company that provides annual physical examinations
o individuals employed at corporations that offer EHE
ervices as part of their corporate wellness plan. The
xaminations are offered to the employees of participat-
ng companies at no cost to the employee. Companies
iffer in their policies regarding which levels of employ-
es are eligible for the physical examination, but many
ompanies offer it to all levels of employees and their
Abbreviations used in this paper: EHE, Executive Health Exams
nternational, Inc.
© 2008 by the AGA Institute
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1312 RUNDLE ET AL GASTROENTEROLOGY Vol. 134, No. 5pouses. The physical examinations take place at 6 EHE
wned centers (New York City, NY; Stamford, CT; Mor-
istown, NJ; Houston, TX; Chicago Il; and Boston, MA)
nd at a network of over 60 physician offices across the
ountry. The network offices meet EHE quality control
tandards for the examination procedures. Examination
ata are recorded electronically in a centralized digital
edical record system maintained by EHE. Data can be
etrieved from the centralized digital medical record sys-
em and are stripped of identifiers before being compiled
nto files that can be read by standard statistical pro-
rams. The Columbia University Medical Center Institu-
ional Review Board approved the study protocol and
esignated it as “Non-Human Research” involving dei-
entified records previously collected for other purposes.
Colonoscopy screening is provided as part of the well-
ess examination for all adults over age 40 years. At the
ime of initial examination, examinees fill out a question-
aire, which collects demographic, risk factor, and clini-
al history information. Those 40 years of age and older
ho are eligible and agreeable are then scheduled to
eturn for their colonoscopic examination.
We collected deidentified data on colonoscopies per-
ormed on individuals ages 40–49 years as well as indi-
iduals ages 50–59 years during the 27-month period
rom January 2004 through March 2006. We excluded
olonoscopies that did not reach the cecum as well as
olonoscopies for which the clinical indication was other
han for screening purposes (eg, anemia, abdominal pain,
r diarrhea). To ensure that the population was of aver-
ge risk, we excluded from the analysis individuals who
ad a family history of colon cancer or a personal history
f inflammatory bowel disease or any malignancy other
han skin cancer. We collected data on the size, location,
nd number of adenomas per patient from the colonos-
opy reports. The presence of adenomatous polyps, vil-
ous features, high-grade dysplasia, and carcinoma was
efined by pathology review.
Adenoma size was determined by visual estimate with
able 1. Demographics of Subjects Undergoing Screening
Colonoscopy
Ages 4049 y
n  553
Ages 5059 y
n  352
ge, y Median, 45.58 Median, 53.71
Range, 40.1349.99 Range, 50.0359.74
ex, n (%)
Male 417 (75) 271 (77)
Female 136 (25) 81 (23)
ace, n (%)
White 393 (71) 258 (73)
Nonwhite 160 (29) 94 (27)
ody size, n (%)
Normal weight 191 (36) 110 (33)
Overweight 258 (49) 154 (47)
Obese 79 (15) 68 (21)he use of the open biopsy forceps or was determined pfter removal. Adenomas considered advanced were those
hat were 1 cm in diameter or that contained villous
eatures or high-grade dysplasia. In instances in which an
ndividual had multiple adenomas, we reported informa-
ion on the largest. In instances in which 2 or more
denomas were the same size, information on the most
istal was reported.
We compared the prevalence and location of colorectal
denomas, advanced adenomas, and carcinomas among
ndividuals 40–49 years to those 50–59 years. We used
he 2 and Fischer exact tests for comparisons of propor-
ions.
Results
A total of 905 colonoscopies was performed dur-
ng the study period that were eligible for analysis. Of
hese, 553 colonoscopies were of patients ages 40–49
ears, and 352 colonoscopies were of patients ages 50–59
ears. The demographics of the subjects included in the
nalysis are listed in Table 1. Both groups were predom-
nantly male (75% in the 40–49 group and 77% in the
0–59 group) and were drawn largely from New York
ity and Houston, TX. The preparation was character-
zed as excellent or average in 87% of patients in the
0–49 years age bracket and in 85% of the 50–59 years
ge bracket (P  .70). Moderate or extreme technical
ifficulty was reported in 11% and 13% of the patients
n the 40–49 and 50–59 years age brackets, respec-
ively (P  .56).
A total of 135 patients had 1 or more adenomas with
uniform prevalence of findings by age group. The prev-
lence of adenomas in the 2 age brackets is illustrated in
able 2. Among the 40–49 years age group, 79 (14%, 95%
onfidence interval [CI]: 12%–18%) individuals had 1 or
ore adenomas, and, among the 50–59 years age group,
6 (16%, 95% CI: 12%–20%) had 1 or more adenomas (P
50). After controlling for sex, race, body size, and clinical
acility location, age group remained unassociated with
denoma prevalence (P  .52). In the 40–49 years age
roup, 11 of these patients (2% of the total screened, 95%
I: 1%–4%) had an advanced neoplasm, whereas, in the
0–59 years age group, 13 of the patients had an ad-
anced neoplasm (4% of the total screened, 95% CI: 2%–
%). The number needed to screen to find 1 advanced
able 2. Number of Patients With No Adenoma, 1 or More
Adenoma, and 1 or More Advanced Neoplasm
Ages 4049 y,
n (%)
Ages 5059 y,
n (%)
o adenoma 474 (86) 296 (84)
onadvanced adenoma 68 (12) 43 (12)
dvanced neoplasia 11 (2) 13 (4)
OTE. There was no statistically significant difference between the 2
ge brackets with regard to prevalence of adenomas (P  .50) or
revalence of advanced adenomas (P  .12).
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May 2008 COLONOSCOPY IN AVERAGE-RISK PATIENTS 1313eoplasm in the 40–49 years age group is 50 (95% CI:
9–100), and, in the 50–59 years age group, the number
s 27 (95% CI: 16–50). Among the 40–49 years age group,
en accounted for 73% of the advanced lesions, and,
mong the 50–59 years age group, men accounted for
9% of the advanced lesions (P  .85). There was 1
denocarcinoma found in the entire cohort, occurring in
he 50–59 years age group, yielding a carcinoma preva-
ence of 0.3% in this age group. The prevalence of ad-
anced colorectal neoplasia did not differ significantly
etween the 2 age groups (P  .12). In the 40–49 years
ge group, the prevalence of 1 or more adenomas among
omen was 11% and among men was 15% (P  .21), and,
n the 50–59 years age group, the prevalence was 15% in
en and 16% in women (P  .76).
The distribution of the number of adenomas per pa-
ient is illustrated in Table 3. Of the 40–49 years age
roup with adenomas, 57 (72%) had 1 adenoma, 17 (22%)
ad 2 adenomas, and 5 (6%) had 3 or more adenomas. Of
he 50–59 years age group with adenomas, 45 (80%) had
adenoma, 8 (14%) had 2 adenomas, and 3 (5%) had 3 or
ore adenomas. The difference in adenoma number be-
ween these 2 age groups was not statistically significant
P  .53). The average and median adenoma size did not
ary by group (40–49 years age group mean, 4.82 mm;
edian, 4.00 mm; 50–59 years age group mean, 5.05 mm;
able 3. Number of Patients With 1, 2, or 3 Adenomas
Among Patients With Adenomas in the 2 Age
Brackets
Number of adenomas
Ages 4049
y, n (%)
Ages 5059
y, n (%)
ne adenoma 57 (72) 45 (80)
wo adenomas 17 (22) 8 (14)
hree or more adenomas 5 (6) 3 (5)
OTE. P  .53 for the difference in adenoma number.
able 4. Prevalence of Adenomas by Location and Age Group
Age group, y Rectum Sigmoid Descending colon Splenic fle
4049 8 (10) 13 (17) 10 (13) 11 (14
5059 5 (9) 8 (14) 4 (7) 6 (11
OTE. The difference in distribution of adenomas in these 2 age gro
able 5. Prevalence of Adenomas, Advanced Neoplasms, an
5059 Years
Study
Percentage of patients
with adenomas
urrent study 4049 y: 14
5059 y: 16
mperiale et al9 4049 y: 11
5059 y: not statededian, 4.00 mm, P  .78). The prevalence of adenomas
reater or equal to 5 mm in size was 43% in the 40–49
ears age bracket and 45% in the 50–59 years age bracket
P  .85).
The distribution of adenomas throughout the colon in
he 2 groups is detailed in Table 4 and did not vary by age
roup (P  .37). The largest adenomas found within an
ndividual were present proximal to the splenic flexure in
7% and 59% of the 40–49 and 50–59 years age groups,
espectively (P  .17). Among those with adenomas, the
revalence of individuals without adenomas at or distal
o the splenic flexure was 41% in the 40–49 years age
roup and 54% in the 50–59 years age group (P  .13).
Discussion
Despite the substantial morbidity associated with
olorectal cancer and the widespread adoption of screen-
ng recommendations that apply to asymptomatic aver-
ge-risk persons at age 50 years, the prevalence of pre-
eoplastic colorectal adenomas in the preceding decade
as had little study. The sole previous analysis of the
revalence of adenomas in this age group in the United
tates found an adenoma prevalence of 11%, with a preva-
ence of advanced adenomas of 3.5%, rates similar to our
ndings (Table 5).9 Similar findings in this age group were
eported among average-riskmen in South Korea, although,
n that study, the prevalence of adenomas and advanced
eoplasia among women was significantly lower.10
Prior studies of asymptomatic patients older than 50
ears found a prevalence of adenoma and advanced neo-
lasia that was considerably higher than that in our
ohort. For example, in one large cohort, the prevalence
f colorectal neoplasia was 37.5%.4 However, more than
wo thirds of this cohort consisted of subjects between 60
nd 75 years of age. Moreover, 13.9% of individuals in
hat population had 1 or more first-degree relatives with
history of colorectal cancer. Other cohorts demonstrat-
cation, n (%)
Transverse colon Hepatic flexure Ascending colon Cecum
12 (15) 8 (10) 11 (14) 6 (8)
6 (11) 6 (11) 8 (14) 13 (23)
as not statistically significant (P  .37).
lorectal Cancer Among Patient Groups Aged 4049 and
Percentage of patients with
advanced neoplasms
Percentage of patients
with colorectal cancer
4049 y: 2 4049 y: 0
5059 y: 4 5059 y: 0.3
4049 y: 3.5 4049 y: 0
5059 y: 4.1 5059 y: 0.5Lo
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1314 RUNDLE ET AL GASTROENTEROLOGY Vol. 134, No. 5ng a similarly high prevalence of adenomas among
symptomatic patients older than 50 years had a large
roportion of patients older than 59 years and included
hose with a family history of colorectal cancer.11,12 Our
tudy excluded such patients to compare the prevalence
f colorectal neoplasia in 2 age deciles in an average-risk
opulation. This most likely accounts for the relatively
ower prevalence of adenomas in our cohort as compared
ith prior studies.
We did not find a significant difference in the overall
revalence of adenomas between the 40–49 years age
roup and the 50–59 years age group. However, we did
bserve an increase in the prevalence of advanced neo-
lasms in the 50–59 years age group compared with the
0–49 years age group. Although this near doubling of
he prevalence of advanced neoplasms was not statisti-
ally significant, we suspect that there is a true rise in the
revalence of advanced neoplasms between these 2 de-
ades that our study was not adequately powered to
bserve. Post hoc power analyses show that the smallest
ifference in the prevalence of advanced tumors that
ould be observed with 80% power was 2% in the 40–49
ears age group vs 6% in the 50–59 years age group. This
ise was noted as well in the study by Imperiale et al, in
hich the rise in prevalence of advanced neoplasms con-
inued in subsequent decades of life.9 A rise in the prev-
lence of advanced neoplasms in the 50–59 years age
roup as compared with the 40–49 years age group
ould account for the well-established subsequent par-
llel rise in the prevalence of colorectal cancer in later
ecades.
An actuarial analysis of colonoscopy for colorectal can-
er screening is required to determine whether screening
he asymptomatic population beginning at age 40 years
ould prevent enough morbidity and mortality to be
ost-effective; such cost-efficacy analyses have been per-
ormed on colonoscopy as a screening modality but have
enerally considered age 50 years to be the age of initia-
ion of screening,13,14 with only one such analysis con-
idering 1-time screening at age 45–49 years.15
A recent study by Regula et al, analyzing the results of
national screening program in Poland, found that the
revalence of advanced colorectal neoplasia in men ages
0–49 years was similar to that of women ages 50–59
ears, suggesting that the age at which to commence
creening should be sex specific.16 However, individuals
n the 40–49 years age bracket in that study were eligible
or screening only if there was a family history of cancer
f any kind; this does not represent the average-risk
opulation, even when limiting the analysis to those with
family history of malignancy other than colorectal
ancer. Nonetheless, our results are similar in that,
mong men, the prevalence of adenoma was the same in
he 2 age groups and was slightly higher among 50–59
ears of age women than among 40–49 years of age
omen.Our study has a number of limitations. As noted above,
he population is predominantly male and white, limiting
he ability to evaluate sex and race as a risk factor for
olorectal neoplasia because of a relative lack of compara-
ors. Dietary and medication data, which may affect devel-
pment of adenomas, were not collected; nevertheless, one
ould not expect there to be a large difference in diet or
edication use between the 2 age brackets that would have
substantial impact on our findings. Because this was an
bservational study, the decision of the patient to proceed
ith colonoscopy during ages 40–49 years may have been
ue to factors associated with an increased risk of adenoma
r carcinoma, such as rectal bleeding. We excluded from our
nalysis those patients who were noted to have an indica-
ion for colonoscopy other than screening, but the possibil-
ty remains that some of the patients in the 40–49 years of
ge bracket were of above-average risk for colorectal neopla-
ia. Furthermore, our study focused on an employed pop-
lation provided with wellness examinations by their em-
loyers. Thus, the results may not be generalizable to other
roups.
Our analysis demonstrates that there is little difference
n the overall prevalence of colorectal adenomas when we
ompared asymptomatic individuals ages 40–49 years to
hose ages 50–59 years. Despite the similar adenoma
revalence between the 2 age groups, we detected an
ncreased prevalence of advanced neoplasia in the
0–59 years age group that was not statistically signif-
cant, possibly because of sample size limitations. We
uspect that future sufficiently powered studies will
emonstrate a true rise in the prevalence of advanced
eoplasia when comparing these 2 age groups. Future
tudies are also required to determine the cost-efficacy
f screening with colonoscopy at age 40 years and to
evelop noninvasive methods to further risk stratify
hose whom we currently consider to be at average risk
or colorectal cancer.
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